Growth Metrics

Healthequity (HQY) Cash & Equivalents (2016 - 2026)

Healthequity has reported Cash & Equivalents over the past 14 years, most recently at $318.9 million for Q1 2026.

  • Quarterly results put Cash & Equivalents at $318.9 million for Q1 2026, up 7.76% from a year ago — trailing twelve months through Jan 2026 was $318.9 million (up 7.76% YoY), and the annual figure for FY2026 was $318.9 million, up 7.76%.
  • Cash & Equivalents for Q1 2026 was $318.9 million at Healthequity, up from $309.3 million in the prior quarter.
  • Over the last five years, Cash & Equivalents for HQY hit a ceiling of $404.0 million in Q1 2024 and a floor of $161.2 million in Q2 2022.
  • Median Cash & Equivalents over the past 5 years was $290.3 million (2023), compared with a mean of $276.4 million.
  • Biggest five-year swings in Cash & Equivalents: plummeted 78.11% in 2022 and later skyrocketed 64.14% in 2023.
  • Healthequity's Cash & Equivalents stood at $210.2 million in 2022, then surged by 58.93% to $334.1 million in 2023, then decreased by 3.56% to $322.2 million in 2024, then fell by 4.01% to $309.3 million in 2025, then increased by 3.13% to $318.9 million in 2026.
  • The last three reported values for Cash & Equivalents were $318.9 million (Q1 2026), $309.3 million (Q4 2025), and $304.5 million (Q3 2025) per Business Quant data.